Navigation Links
Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
Date:5/5/2009

ROCKVILLE, Md., May 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today the start of its Phase 1B trial for SQ109 with the dosing of the first cohort of volunteers. SQ109, a new diamine antibiotic intended to replace one or more of the current first-line antitubercular drugs and simplify patient therapy, was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows superior antibacterial activity against drug sensitive and both multi-drug resistant and extensively-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The Phase 1B study will assess safety, pharmacokinetics and tolerability of multiple ascending doses of SQ109 in three cohorts of healthy volunteers.

"We are pleased to begin this Phase 1B safety trial and to continue the clinical development of SQ109, a potentially valuable new drug candidate for the treatment of both uncomplicated and drug resistant TB," said Dr. Carol Nacy, Sequella CEO. "With the growing number of new TB cases within HIV-infected populations, there is no time to waste. Clinicians and patients alike are desperate for new drugs to shorten treatment times and improve patient outcomes. In a global world, the safety assessment of a new drug candidate with the antitubercular properties of SQ109 is an important milestone for patients on every continent, including North America."

The SQ109 Phase 1B trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), through a contract awarded to Dynport Corporation. The investigative site is the Quintiles Phase 1 facility in Overland Park, Kansas.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializin
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
4. Psylin Neurosciences Commences Development of Compound for Depression
5. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , KING OF PRUSSIA, Pa., Nov. 30 /PRNe... company specializing in interactive marketing s... today announced the launch of its HATCH Consulti...m/hatch ). Aligning strategic experts across a ra...ting, the HATCH Consulting team is committed to gu...
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNe...ey guidance document for the publication of compan...nline today by the British Medical Journal (BMJ). ...ion of the importance of providing support and gui...ication of study results in the peer-reviewed medi...
(Date:11/30/2009)... , ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstC...oday it has completed enrollment in the Phase II c...(2008/2009 recommended strains) VLP vaccine candid...der adults). This randomized, double-blind, activ...bility and immunogenicity of two different doses (...
(Date:11/30/2009)... , BOSTON and COPENHAGEN, Nov. 30 /PRNewswir...nounced today that the Harvard Medical School ICCB...ognized as a MicroRNA Screening Center of Excellen...cal School, and associated hospitals and instituti...le and RNAi libraries. ,, MicroRNAs are a novel...
Breaking Biology Technology:Cadient Interactive Announces the Launch of HATCH Consulting Services 2Cadient Interactive Announces the Launch of HATCH Consulting Services 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3
...t the promise of Silicon Valley has joined the doo...opriate time to revisit the importance of technolo...ions of dollars have been spent on marketing the s... must come into a business or industry than goes o...g about technology that matters is what people and...
...ing back, you couldn,t tell it by the Consumer Ele... product releases, a near-electric buzz among atte...een at a technology tradeshow in recent years. In ...omic indicator, this market is coming back strong....nes more reliable than the wait for a hackney. , ...
...o everything these days - from removing tattoos to... dairy state of Wisconsin, lasers have been harnes...,Xiaochun Li, a University of Wisconsin-Madison me...long with graduate student Hongseok Choi, has beco...ining" technique, primarily used in laser eye surg...
Other Biology Technology:Look at the New Economy, Just Like the Old Economy 2Consumers Lead Tech Market Comeback 2Consumers Lead Tech Market Comeback 3Wisconsin Engineers Devise Cutting-Edge Method to Cut Cheese 2Wisconsin Engineers Devise Cutting-Edge Method to Cut Cheese 3
(Date:11/30/2009)... PITTSBURGHA University of Pittsburgh team overca...materials such as those that could lead to more ef...der car exhaust less toxic. The researchers report...ration of high-temperature stability in metallic n...s hampered by a vulnerability to extreme heat. , ...
(Date:11/30/2009)... The Editors of The Journal of Experimental Biol... from Centre National de la Recherche Scientifique...is the winner of this year,s JEB Outstanding Pap...an outstanding achievement and is intended to enco... JEB Editor-in-Chief, and adds that ,we truly app...
(Date:11/30/2009)... Take advantage of lower early bird registration ...eoporosis congress of 2010 at http://www.iofwco-e... congress of the International Osteoporosis Founda...nd Economic Aspects of Osteoporosis and Osteoarthr...ound the world are expected to attend. The excitin...
Breaking Biology News(10 mins):First metallic nanoparticles resistant to extreme heat 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4School of Health Management Honors 162 Graduating Students 51979 1School of Health Management Honors 162 Graduating Students 51979 2Essilor 3A First Half 2009 Revenue 13074 1Essilor 3A First Half 2009 Revenue 13074 2Essilor 3A First Half 2009 Revenue 13074 3Essilor 3A First Half 2009 Revenue 13074 4Essilor 3A First Half 2009 Revenue 13074 5Is a society with smokers profitable 3F 51975 1Is a society with smokers profitable 3F 51975 2Is a society with smokers profitable 3F 51975 3
...nguists have argued that certain patterns of langu...ans -- perhaps the only uniquely human component o...hicago and the University of California San Diego ...h patterns and distinguish between them in Sturnus...April 27, 2006, issue of Nature, the researchers s...
...have discovered that a dominant hyena puts her cub...assing on high levels of certain hormones that mak...xually advanced. , The report, published in the Ap...als to demonstrate a relationship between a female...fspring,s behavior through prenatal hormone transf...
...t can harm the brain immediately after a stroke ma...new research. Insights from the study could change...or effective treatment from a couple of hours to a...s for drug development. , Working with rats, a te...Radiology and Neurology found that the enzyme matr...
Other Biology News:'Uniquely human' component of language found in gregarious birds 2'Uniquely human' component of language found in gregarious birds 3'Uniquely human' component of language found in gregarious birds 4'Uniquely human' component of language found in gregarious birds 5'Bad' enzymes may wear white hats after stroke 2'Bad' enzymes may wear white hats after stroke 3'Bad' enzymes may wear white hats after stroke 4
Fingerprinting II Informatix, optional matrix types module from Bio-Rad
... Lines ,High Quality, Functionally-Validated, Ion ...for having a critical role in nerve and muscle fun..., CNS and the heart. Drugs that modulate ion chann...uch as neuropathic pain, cardiac arrhythmia, hyper...
...are derived from frozen embedded tissue blocks, wh...edures to ensure the highest quality. Tissues of e...tioned at a thickness of 7 microns and mounted on ...ter) in comparison to core sections made using Tis...
...ations or for use in an automated line. The StatMa...fold provides greater ease, speed, convenience, an...StatMatic II can be connected to a range of bottle...ne-handed operation -- in a matter of seconds.,T...
Biology Products: